Clinical trial
Treatment of Arthritis With Syk Kinase Inhibition (TASKI-1)
NCT00326339 · Rigel Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00326339 |
|---|---|
| Title | Treatment of Arthritis With Syk Kinase Inhibition (TASKI-1) |
| Official title | A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose, Dose Ranging Study to Evaluate Up to Three Doses of R935788 in Rheumatoid Arthritis Patients Failing to Respond to Methotrexate |
| Lead sponsor | Rigel Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Rheumatoid Arthritis |
| Intervention type | Drug |
| Interventions | R788, Placebo |
| Enrollment | 189 |
| Start date | Aug 1, 2006 |
| Primary completion | Oct 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | May 16, 2006 |
| Last update posted | Apr 20, 2009 |
| Countries | Mexico, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: